硼替佐米增强P16蛋白表达诱导骨髓瘤细胞衰老

目的：研究蛋白酶体抑制剂硼替佐米诱导骨髓瘤RPMI8226、MMH929细胞衰老作用,并进一步探讨其作用机制。方法：硼替佐米0.1-100nmol/L处理骨髓瘤RPMI8226、MMH929细胞48、72h,MTT法检测细胞存活率、药物IC50值。选择药物IC50值1/10剂量处理骨髓瘤RPMI8226、MMH929细胞0、24、48H后检测衰老相关β-半乳糖苷酶染色率。流式细胞术检测细胞周期情况及凋亡率。Western-blot检测相关蛋白表达。结果：硼替佐米处理骨髓瘤细胞RPMI8226、MMH929后48小时IC50值：RPMI8226：19.05 nmol/L,MMH929：18.45nmol/L。以硼替佐米2 nmol/L处理骨髓瘤RPMI8226、MMH929细胞0、24、48H后发现β-半乳糖苷酶染色率、细胞G0/G1期比例明显上升与药物作用时间呈正相关,Western-blot检测细胞周期调控蛋白发现P53、PTEN蛋白无变化,P16蛋白与药物作用时间正相关。结论：硼替佐米通过增强P16蛋白表达诱导骨髓瘤细胞RPMI8226、H929衰老。     

雷公藤内酯醇对多发性骨髓瘤细胞凋亡及组蛋白H3K4甲基化的影响

目的：探讨雷公藤内酯醇（TPL）对多发性骨髓瘤RPMI8226细胞增殖、凋亡和组蛋白H3K4甲基化的影响。方法：以人多发性骨髓瘤细胞株RPMI8226为研究对象,在不同浓度（10、20、40、80、160 nmol/L） TPL中共培养不同时间（24 h、48 h、72 h）后,采用噻唑蓝（MTT）法检测细胞增殖活性;流式细胞术检测细胞凋亡和细胞周期;Western blot法检测组蛋白H3K4me2、H3K4me3的甲基化状态,实时荧光定量RT-PCR分析组蛋白甲基化酶SMYD3和组蛋白去甲基化酶LSD1的表达水平。结果：TPL对RPMI8226细胞有明显的增殖抑制作用,呈剂量和时间依赖性（P<0.05）;TPL对RPMI8226细胞有明显诱导凋亡的作用,并且随着TPL作用浓度的增加,细胞凋亡比例逐渐增加（P<0.05）;同时TPL还可以诱导RPMI8226细胞周期阻滞于G₂/M期;TPL以浓度依赖性降低组蛋白H3K4me2、H3K4me3的甲基化水平（P<0.05,P<0.01）,并抑制SMYD3和上调LSD1的表达（P<0.05）。结论：TPL可抑制RPMI8226细胞增殖、引起细胞周期阻滞于G₂/M期,并诱导其凋亡;通过抑制组蛋白甲基化酶SMYD3和增强组蛋白去甲基化酶LSD1的表达,降低组蛋白H3K4me3和H3K4me2的甲基化水平,这可能是TPL诱导多发性骨髓瘤细胞凋亡和抗肿瘤作用的机制之一。     

KANK1对子宫内膜癌细胞增殖及迁移的影响

摘要 目的：研究KANK1在子宫内膜癌中的表达以及对子宫内膜癌细胞增殖及迁移的影响。方法：（1）TCGA数据库分析KANK1在子宫内膜癌中的表达和生存期分析。（2）采用实时荧光定量聚合酶链反应验证转染KANK1质粒的效果。采用Ishikawa和ECC1这两种子宫内膜癌细胞来探讨KANK1对子宫内膜癌的细胞周期和凋亡的影响。通过Western blot检测细胞周期相关蛋白的表达,以及流式细胞术检测细胞周期和凋亡水平。（3）通过Transwell小室实验和划痕实验检测细胞的侵袭和转移能力。结果：TCGA数据库分析发现KANK1在子宫内膜癌中低表达且与患者预后良好相关。过表达KANK1下调了Cyclin D1和Cyclin D2的蛋白水平,并将细胞周期阻滞在G1期。流式细胞术检测发现过表达KANK1组的细胞凋亡水平（Ishikawa：22.7%;ECC1：19.0%）比对照组（Ishikawa：18.1%;ECC1：15.3%）高,差异具有统计学意义。Transwell迁移和侵袭实验结果表明过表达KANK1组的子宫内膜癌细胞侵袭和转移能力减弱。结论：本研究证明了KANK1在子宫内膜癌中发挥抑癌作用。KANK1高表达与子宫内膜癌的预后良好成正相关。KANK1通过抑制癌细胞周期和促进肿瘤细胞凋亡发挥抑制子宫内膜癌增殖的作用。此外,KANK1抑制了子宫内膜癌的侵袭和转移。     

MiR-1-3p通过抑制CAPRIN1调控胰腺癌发生发展

摘要 目的：探讨miR-1-3p在胰腺癌发生发展中的分子机制。方法：以MIA-PaCa-2,SW 1990为研究目标,通过qRT-PCR技术检测miR-1-3p的表达量,利用TargetScan和miRDB数据库预测miR-1-3p的下游靶基因及结合位点,并通过构建双荧光素酶报告基因,进一步确认miR-1-3p与靶基因的结合。利用CCK8细胞增殖实验及平板克隆形成实验检测过表达miR-1-3p及敲低CAPRIN1对细胞增殖的作用;利用流式检测细胞周期;利用蛋白质免疫印迹方法检测miR-1-3p对CAPRIN1及其下游基因的影响;通过流式来确认,过表达miR-1-3p及敲减CAPRIN1基因对细胞周期的影响。结果：miR-1-3p在胰腺癌细胞MIA-PaCa-2,SW 1990中低表达;miR-1-3p直接与CAPRIN1的3''-untranslated region (3''- UTR)结合;过表达miR-1-3p或抑制CAPRIN1基因的表达可明显抑制胰腺癌细胞的增殖能力,同时也产生细胞周期阻滞。结论：miR-1-3p通过抑制CAPRIN1基因表达,而产生细胞周期阻滞进而抑制胰腺癌细胞的增殖能力。     

抑制自噬促进冬凌草甲素诱导的多发性骨髓瘤细胞凋亡涉及胞内ROS产生

目的本实验主要研究冬凌草甲素诱导多发性骨髓瘤发生自噬、凋亡,两者之间的关系以及所涉及的相关机制。方法利用MTT比色法检测冬凌草甲素对多发性骨髓瘤RPMI8226细胞的增殖活性影响;透视电镜观察细胞内凋亡和自噬的形态学改变;TUNEL检测细胞凋亡;分别利用以下技术检测处理后的细胞内的自噬变化:使用QDs605nm-Anti-LC3荧光探针以及免疫荧光技术定位细胞胞内LC3Ⅰ和LC3Ⅱ蛋白,利用western blot免疫印记技术检测Beclin 1蛋白表达水平;利用DCFH-DA探针以及流式细胞术检测细胞胞内ROS水平。结果冬凌草甲素能明显抑制RPMI8226细胞增殖,其抑制作用呈时间、剂量依赖性;冬凌草甲素能同时诱发细胞凋亡、自噬和胞内ROS产生;NAC完全抑制胞内ROS产生后冬凌草甲素诱导的细胞凋亡消失;3-MA抑制自噬后,冬凌草甲素诱导的胞内ROS产生进一步增多,凋亡增多。结论冬凌草甲素能明显抑制RPMI8226细胞增殖;冬凌草甲素同时诱发细胞凋亡和自噬;胞内ROS产生介导冬凌草甲素诱导的凋亡;凋亡为细胞死亡的主要途径,而自噬通过下调胞内ROS产生抑制凋亡。     

奥曲肽联合黄芩素抑制胰腺神经内分泌肿瘤细胞增殖和迁移

摘要 目的：探讨奥曲肽（Octreotide，Oct）联合黄芩素（Baicalein，BE）对胰腺神经内分泌肿瘤（Pancreatic neuroendocrine neoplasms, pNENs）的影响。方法：用不同浓度的奥曲肽和黄芩素处理pNENs来源的QGP-1细胞，CCK8法检测细胞的存活率，以其半抑制浓度（IC₅₀）的比值作为浓度梯度进行联合用药，并用Compusyn软件进行联合指数（CI）分析，取细胞毒性效应适中且CI值较低的浓度（奥曲肽150 μmol/L，黄芩素20 μmol/L）进行表型实验。将QGP-1细胞分为四组：对照组、奥曲肽组、黄芩素组、奥曲肽和黄芩素联用组。通过克隆形成实验、EdU增殖检测、划痕实验、细胞凋亡和周期检测评价四组细胞的增殖、迁移能力以及凋亡和细胞周期的情况。结果：药物处理24 h后，奥曲肽和黄芩素均能够呈浓度依赖性抑制QGP-1细胞增殖（P<0.05），奥曲肽的IC₅₀为329.90 μmol/L，黄芩素的IC₅₀为42.86 μmol/L，两者IC₅₀的比值约为7.5:1，联用组细胞活性明显低于单药组（P<0.05），且CI值随着药物浓度的增加而降低。克隆形成实验和EdU增殖检测结果表明，奥曲肽和黄芩素均可抑制QGP-1细胞增殖（P<0.05），且联用组的克隆形成率和EdU阳性细胞百分比均低于单药组（P<0.05）。划痕实验结果表明，奥曲肽和黄芩素均可降低QGP-1细胞的迁移率（P<0.05），且联用组的迁移率低于单药组（P<0.05）。细胞凋亡和周期检测结果表明，黄芩素可促进QGP-1细胞的凋亡（P<0.05），并使QGP-1细胞阻滞于G0/G1期（P<0.05），而奥曲肽对QGP-1细胞的凋亡和细胞周期无明显影响（P>0.05），两药联用对其凋亡和周期无协同作用。结论：奥曲肽和黄芩素联合用药可协同抑制QGP-1细胞增殖和迁移，对细胞凋亡和周期无明显协同作用。     

LncRNA MYU对胶质瘤细胞周期分布、增殖、转移和凋亡以及PI3K/Akt信号通路的影响

摘要 目的：探讨长链非编码RNA（LncRNA）MYU对胶质瘤细胞周期分布、细胞增殖、迁移、侵袭和凋亡的影响,并初步探讨其作用机制。方法：实时荧光定量PCR（RT-qPCR）检测人脑正常胶质细胞HEB和胶质瘤细胞（U-251MG、A172、SHG139）中LncRNA MYU的表达情况。选取SHG139细胞,分为正常对照（NC）组、si-con组、si-LncRNA MYU组进行转染实验,行RT-qPCR检测转染效果。分别采用流式细胞术、细胞计数试剂盒（CCK-8）、Transwell实验检测沉默LncRNA MYU对SHG139细胞周期分布和凋亡、细胞增殖、细胞迁移和侵袭的影响。蛋白免疫印迹（Western blot）法检测基质金属蛋白酶2（MMP-2）、MMP-9、裂解的半胱氨酸天冬氨酸蛋白酶3（Cleaved caspase-3）、Cleaved caspase-9以及磷脂酰肌醇-3-羟激酶/蛋白激酶B（PI3K/Akt）信号通路相关蛋白表达情况。结果：LncRNA MYU在胶质瘤细胞株中比人脑正常胶质细胞中的表达水平显著升高（P＜0.05）,因此选择表达量最高的SHG139细胞进行转染实验。沉默LncRNA MYU能够显著诱导SHG139细胞G0-G1期阻滞、抑制细胞增殖、迁移和侵袭并诱导细胞凋亡（P＜0.05）。沉默LncRNA MYU可显著抑制MMP-2、MMP-9、p-PI3K和p-AKT表达并促进Cleaved caspase-3、Cleaved caspase-9表达（P＜0.05）。结论：沉默LncRNA MYU可诱导胶质瘤细胞G0-G1期阻滞,抑制细胞增殖、迁移和侵袭,促进细胞凋亡,其机制可能与抑制PI3K/AKT信号通路有关。     

新合成黄腐酚类似物联合顺铂对宫颈癌细胞化疗增敏作用的研究

摘要 目的：探讨新合成黄腐酚类似物联合顺铂对宫颈癌Hela细胞化疗敏感性的影响及其机制。方法：以不同浓度（5、7.5、15、20 μmol/L）黄腐酚类似物处理宫颈癌Hela细胞和正常MRC-5细胞48 h后,MTT实验检测细胞增殖活力并计算出黄腐酚类似物对2种细胞的半数抑制浓度(IC₅₀);采用MTT实验进一步观察IC₅₀最低的黄腐酚类似物联合顺铂对Hela和MRC-5细胞增殖活力的影响,采用流式细胞仪检测Hela细胞周期和凋亡情况,Western blot法检测Hela细胞中凋亡相关蛋白表达变化。结果：黄腐酚类似物a8、a13、b11和b12对宫颈癌Hela细胞增殖均有一定的抑制作用,且a13的IC₅₀值最小;另外,这4种浓度的黄腐酚类似物对正常MRC-5细胞有轻微的抑制作用,且a13的IC50值最大。与对照组比较,顺铂组、a13组、顺铂+a13组中正常MRC-5细胞存活率差异均无统计学意义（P<0.05）,但顺铂组、a13组和顺铂+a13组中宫颈癌Hela细胞存活率、G2/M期细胞百分比和B淋巴细胞瘤-2基因（Bcl-2）蛋白表达水平均明显降低,而G0/G1期细胞百分比、细胞凋亡率和细胞中细胞色素C（Cyt-c）、Bcl-2关联X蛋白（Bax）、活化的半胱氨酸天冬氨酸蛋白酶3（Cleaved Caspase-3）、活化的半胱氨酸天冬氨酸蛋白酶9（Cleaved Caspase-9）蛋白表达水平均明显升高,且顺铂+a13组中上述指标变化幅度明显大于顺铂组、a13组（P<0.05）。结论：黄腐酚类似物与顺铂联合可协同抑制宫颈癌Hela细胞增殖,表现良好的化疗增敏效果,其作用机制可能与阻滞细胞周期进程和调控凋亡相关蛋白表达促进细胞凋亡有关。     

脂多糖对多发性骨髓瘤细胞增殖的影响及其机制

目的:探讨脂多糖(lipopolysaccharide,LPS)对多发性骨髓瘤细胞增殖的影响及其作用机制。方法:采用LPS作用于多发性骨髓瘤细胞RPMI 8226后,通过MTT法检测细胞的增殖情况,流式细胞术检测细胞周期的变化,Western blot检测NF-κB信号通路中相关蛋白p65和IκB-α的表达情况。结果:随着LPS作用浓度(0-8μg/mL)的增加,RPMI 8226细胞增殖活力呈先上升后下降的趋势,在2μg/m L LPS作用下,RPMI8226细胞的增殖活力最显著(P0.05)。相同浓度的LPS诱导RPMI8226细胞不同时间,其细胞增殖呈时间依赖性。流式细胞术检测结果显示:不同浓度LPS(0.5、1、2μg/mL)作用RPMI 8226细胞后,G0/G1期细胞的比例明显低于对照组(P0.05),S期和G2/M期细胞比例明显增加(P0.05);Western blot检测结果显示:2μg/mL的LPS处理的RPMI8226细胞p65和IΚB-α蛋白的表达明显高于对照(P0.05)。结论:低浓度LPS能够诱导多发性骨髓瘤细胞RPMI 8226的增殖,其作用机制可能与上调信号通路NF-κB中相关蛋白p65和IκB-α有关。     

miR-134-5p靶向抑制PAK3表达增强多发性骨髓瘤细胞的化疗敏感性的研究

摘要 目的：研究miR-134-5p对多发性骨髓瘤（multiple myeloma, MM）化疗敏感性的影响及其可能的作用机制。方法：CCK-8法测定人多发性骨髓瘤细胞KM3及其耐硼替佐米（bortezomib, BTZ）细胞株KM3/BTZ对BTZ的化疗敏感性,RT-PCR法检测KM3和KM3/BTZ细胞株中miR-134-5p和p21活化激酶3（p21 activated kinase 3, PAK3）mRNA的表达,生物信息学软件分析miR-134-5p的靶基因,荧光素酶报告实验进行验证,CCK-8法检测分别抑制miR-134-5p和PAK3后KM3/BTZ的化疗敏感性,Western-blot法检测抑制miR-134-5p后KM3/BTZ细胞株中PAK3蛋白的表达。结果：KM3/BTZ细胞株对BTZ的化疗敏感性显著低于KM3细胞株（P＜0.05）。MiR-134-5p在KM3细胞株的表达显著高于KM3/BTZ细胞株,而PAK3 mRNA在KM3细胞株的表达显著低于KM3/BTZ细胞株（P＜0.05）。PAK3为miR-134-5p的靶基因。MiR-134-5p inhibitor组和PAK3 siRNA组KM3/BTZ细胞株的化疗敏感性显著低于对照组（P＜0.05）。MiR-134-5p inhibitor组PAK3蛋白的相对表达显著高于对照组（P＜0.05）。结论：MiR-134-5p可提高KM3/BTZ细胞株的化疗敏感性,其机制可能与抑制PAK3的表达有关。     

BDNF/TrkB confers bortezomib resistance in multiple myeloma by inducing BRINP3

BackgroundThe proteasome inhibitor bortezomib (BTZ) has significantly improved the survival of multiple myeloma (MM) patients. However, most MM patients still relapse and have drug resistance after BTZ treatment.MethodssiRNA transfection was performed to knock down BDNF and TrkB expression. ELISA, western blot, quantitative polymerase chain reaction, CCK-8 assay, and flow cytometry analysis were performed to analyze the functions of BDNF/TrkB signaling in MM cells.ResultsWe identified a cell-autonomous mechanism that promotes BTZ resistance in MM, prolongs their RPMI 8226/BTZ resistant cell survival and optimizes their proliferating function. Specifically, RPMI 8226/BTZ cells produced the brain derived neurotrophic factor (BDNF) and its receptor TrkB, which served as a survival factor in the RPMI 8226/BTZ resistant environment. BDNF/TrkB induced phosphorylation of STAT3 that upregulated the bone morphogenetic protein/retinoic acid inducible neural-specific 3 (BRINP3).ConclusionsBDNF/TrkB enhanced downstream pathway expression of phosphorylation STAT3 and BRINP3 molecules, promoting RPMI 8226/BTZ cell proliferation and survival.General significanceThese data place BDNF/TrkB at the top of a pSTAT3-BRINP3 survival pathway and link adaptability to BTZ resistant conditions in MM disease.     

Xanthohumol exhibits anti-myeloma activity in vitro through inhibition of cell proliferation,induction of apoptosis via the ERK and JNK-dependent mechanism,and suppression of sIL-6R and VEGF production

BackgroundXanthohumol (XN, a hop-derived prenylflavonoid) was found to exert anticancer effects on various cancer types. However, the mechanisms by which XN affects the survival of multiple myeloma cells (MM) are little known. Therefore, our study was undertaken to address this issue.MethodsAnti-proliferative activity of XN towards two phenotypically distinct MM cell lines U266 and RPMI8226 was evaluated with the MTT and BrdU assays. Cytotoxicity was determined with the LDH method, whereas apoptosis was assessed by flow cytometry and fluorescence staining. The expression of cell cycle- and apoptosis-related proteins and the activation status of signaling pathways were estimated by immunoblotting and ELISA assays.ResultsXN reduced the viability of RPMI8226 cells more potently than in U266 cells. It blocked cell cycle progression through downregulation of cyclin D1 and increased p21 expression. The marked apoptosis induction in the XN-treated RPMI8226 cells was related to initiation of mitochondrial and extrinsic pathways, as indicated by the altered p53, Bax, and Bcl-2 protein expression, cleavage of procaspase 8 and 9, and elevated caspase-3 activity. The apoptotic process was probably mediated via ROS overproduction and MAPK (ERK and JNK) activation as N-acetylcysteine, or specific inhibitors of these kinases prevented the XN-induced caspase-3 activity and, hence, apoptosis. Moreover, XN decreased sIL-6R and VEGF production in the studied cells.ConclusionsERK and JNK signaling pathways are involved in XN-induced cytotoxicity against MM cells.General Significance: The advanced understanding of the molecular mechanisms of XN action can be useful in developing therapeutic strategies to treat multiple myeloma.     

NF-Kappa B Modulation Is Involved in Celastrol Induced Human Multiple Myeloma Cell Apoptosis

Celastrol is an active compound extracted from the root bark of the traditional Chinese medicine Tripterygium wilfordii Hook F. To investigate the effect of celastrol on human multiple myeloma cell cycle arrest and apoptosis and explore its molecular mechanism of action. The activity of celastrol on LP-1 cell proliferation was detected by WST-8 assay. The celastrol-induced cell cycle arrest was analyzed by flow cytometry after propidium iodide staining. Nuclear translocation of the nuclear factor kappa B (NF-κB) was observed by fluorescence microscope. Celastrol inhibited cell proliferation of LP-1 myeloma cell in a dose-dependent manner with IC50 values of 0.8817 µM, which was mediated through G1 cell cycle arrest and p27 induction. Celastrol induced apoptosis in LP-1 and RPMI 8226 myeloma cells in a time and dose dependent manner, and it involved Caspase-3 activation and NF-κB pathway. Celastrol down-modulated antiapoptotic proteins including Bcl-2 and survivin expression. The expression of NF-κB and IKKa were decreased after celastrol treatment. Celastrol effectively blocked the nuclear translocation of the p65 subunit and induced human multiple myeloma cell cycle arrest and apoptosis by p27 upregulation and NF-kB modulation. It has been demonstrated that the effect of celastrol on NF-kB was HO-1-independent by using zinc protoporphyrin-9 (ZnPPIX), a selective heme oxygenase inhibitor. From the results, it could be inferred that celastrol may be used as a NF-kB inhibitor to inhibit myeloma cell proliferation.     

丙戊酸钠协同硼替佐米对RPMI8226细胞的促凋亡作用

目的:以骨髓瘤细胞株RPMI8226为实验对象,观察丙戊酸钠(valproic acid,VPA)和硼替佐米(bortezomib,BZ)对此细胞株的增殖及凋亡的诱导情况。方法:实验分组如下:对照组,VPA单药组(1.0 mmol/L),BZ单药A组(10.0 nmol/L),BZ单药B组(20.0 nmol/L),BZ单药C组(35.0 nmol/L),联合用药A组(VPA1.0 mmol/L+BZ10.0 nmol/L),联合用药B组(VPA 1.0 mmol/L+BZ20.0 nmol/L),联合用药C组(VPA 1.0 mmol/L+BZ 35.0 nmol/L)。用MTT技术检测细胞增殖抑制情况;流式细胞仪检测凋亡比例。结果:丙戊酸钠与硼替佐米单用对RPMI8226细胞株细胞增殖有抑制作用,有细胞凋亡,但丙戊酸钠与硼替佐米协同用药A组、B组、C组增殖抑制可达75.1%及凋亡情况可达68.9%(P0.01)。结论:丙戊酸钠与硼替佐米协同用药后对RPMI8226细胞增殖抑制及诱导凋亡作用更显著,丙戊酸钠对硼替佐米有增敏作用。     

In vitro sensitization of human lymphocytes to a myeloma cell-related antigen

Peripheral blood lymphocytes from normal human donors were cocultivated with cells from two established human multiple myeloma cell lines, RPMI 8226 and K-737, and with lymphoblastoid cells from a third B cell line, RAMM. After a comparison of three methods of lymphocyte sensitization, a 6-day incubation protocol with equal numbers of normal lymphocytes and mitomycin C-treated tumor cells was selected. Cells from the RPMI 8226 myeloma line stimulated the differentiation of lymphocytes into cytotoxic effector cells as measured by ⁵¹Cr release from labeled target cells. The RPMI 8226-sensitized lymphocytes were cytotoxic for myeloma cells (RPMI 8226 and K-737) and for lymphoblastoid cells (RAMM) but not for cells from human lung tumor lines (A549, A427, MB9812), a breast carcinoma line (ALAB), a normal diploid fibroblast line (HSBP), or normal lymphocytes.     

Cell cycle arrest induced by the vitamin D(3) analog EB1089 in NCI-H929 myeloma cells is associated with induction of the cyclin-dependent kinase inhibitor p27

EB1089, a 1,25-dihydroxyvitamin D(3) analog, has been known to have potent antiproliferative properties in a variety of malignant cells in vitro and in vivo. In the present study, we analyzed the effect of EB1089 on human myeloma cell lines. EB1089 inhibited the proliferation of NCI-H929 cells and RPMI8226 cells in a dose-dependent manner among three myeloma cell lines tested. The antiproliferative effect of EB1089 on myeloma cells was related to the expression level of vitamin D receptor. To investigate the mechanism of the antiproliferative effect of EB1089, cell cycle analysis was attempted in EB1089-sensitive NCI-H929 cells. EB1089 (1 x 10(-8) M) efficiently induced G(1) arrest of the cell cycle. Analysis of G(1) regulatory proteins demonstrated that protein levels of CDK2, CDK4, cyclin D1, and cyclin A were decreased in a time-dependent manner, but not those of CDK6 and cyclin E, by EB1089. In addition, EB1089 (1 x 10(-8) M, 72 h) increased the protein level of the CDKI p27 and markedly enhanced the binding of p27 with CDK2 compared to EB1089-untreated cells. Furthermore, the activity of CDK2-associated cyclin kinase was decreased, which was accompanied by the reduction of cyclin-D1-, cyclin-E-, and cyclin-A-associated kinase activities, resulting in the hypophosphorylation of Rb protein. These results suggest that EB1089 can inhibit the proliferation of human myeloma cells, especially NCI-H929 cells, via a G(1) block in association with the induction of p27 and the reduction of CDK2 activity.